Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:713-717
Published online before print August 2, 2004, doi: 10.1161/01.CIR.0000138109.32748.80
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/6/713    most recent
01.CIR.0000138109.32748.80v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okoshi, K.
Right arrow Articles by Lorell, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okoshi, K.
Right arrow Articles by Lorell, B. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CARBACHOL CHLORIDE
Related Collections
Right arrow Contractile function
Right arrow Calcium cycling/excitation-contraction coupling
Right arrow Growth factors/cytokines

(Circulation. 2004;110:713-717.)
© 2004 American Heart Association, Inc.


Original Articles

Neuregulins Regulate Cardiac Parasympathetic Activity

Muscarinic Modulation of ß-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion

Katashi Okoshi, MD; Masaharu Nakayama, MD; Xinhua Yan, MD; Marina P. Okoshi, MD; Adam J.T. Schuldt, BA; Mark A. Marchionni, PhD; Beverly H. Lorell, MD

From the Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (K.O., M.N., X.Y., M.P.O., A.J.T.S., B.H.L.), and NRG Biotech, Arlington, Mass (M.A.M.).

Correspondence to Beverly H. Lorell, MD, Cardiovascular Division–East Campus, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Room RW453, Boston, MA 02215. E-mail blorell{at}bidmc.harvard.edu

Received October 22, 2003; de novo received February 17, 2004; accepted April 26, 2004.

Background— Neuregulins are required for maintenance of acetylcholine receptor–inducing activity of nicotinic receptors in neurons and skeletal muscle, but effects of neuregulins on muscarinic receptors are not known. In the normal heart, parasympathetic activation counterbalances ß-adrenergic activation. To test the hypothesis that neuregulins modify parasympathetic function in the heart, we studied cardiomyocytes from mice heterozygous for neuregulin-1 gene deletion (NRG-1+/–) and examined the effects of ß-adrenergic stimulation on contractility in the presence and absence of the muscarinic agonist carbachol.

Methods and Results— We evaluated contraction and intracellular Ca2+ transients ([Ca2+]i) in left ventricular (LV) myocytes loaded with Fluo-3 from NRG-1+/– and wild-type (WT) mice. Under baseline conditions (0.5 Hz, 1.5 mmol/L [Ca2+]o, 25°C), characteristics of myocyte contraction/relengthening and systolic/diastolic [Ca2+]i were not different between WT and NRG-1+/– mice. The steady-state increases in fractional shortening (FS) and peak-systolic [Ca2+]i in response to isoproterenol were similar in both groups. In WT myocytes stimulated with isoproterenol, carbachol decreased FS, peak-systolic [Ca2+]i, and cAMP levels. In NRG-1+/– myocytes, carbachol did not attenuate either FS or peak-systolic [Ca2+]i, associated with the failure to decrease cAMP levels. Investigation of muscarinic receptor signaling showed no difference of LV protein levels of muscarinic M2 receptors or G protein G{alpha}i1,2, G{alpha}i3, and G{alpha}o subunits.

Conclusions— Cardiomyocytes deficient in neuregulin signaling are unable to adequately counterbalance ß-adrenergic activation by inhibitory parasympathetic activity. This mechanism may contribute to the known increased risk of heart failure in injured human hearts when neuregulin signaling is suppressed.


Key Words: acetylcholine • neuregulins • calcium • contractility • myocytes




This article has been cited by other articles:


Home page
CirculationHome page
K. Lemmens, K. Doggen, and G. W. De Keulenaer
Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure
Circulation, August 21, 2007; 116(8): 954 - 960.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F.-F. Liu, J. R. Stone, A. J. T. Schuldt, K. Okoshi, M. P. Okoshi, M. Nakayama, K. K. L. Ho, W. J. Manning, M. A. Marchionni, B. H. Lorell, et al.
Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H660 - H666.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Lemmens, V. F.M. Segers, G. W. De Keulenaer, K. Okoshi, M. Nakayama, X. Yan, M. P. Okoshi, A. J.T. Schuldt, B. H. Lorell, and M. A. Marchionni
Letter Regarding Article by Okoshi et al, "Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of {beta}-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion" * Response
Circulation, April 5, 2005; 111(13): e175 - e175.
[Full Text] [PDF]